177 related articles for article (PubMed ID: 24535941)
1. Functional polymorphisms in apoptosis pathway genes and survival in patients with gastric cancer.
Gu D; Du M; Tang C; Chu H; Xu Z; Huo X; Gong W; Tang Y; Zhou J; Tong N; Xu Y; Zhang Z; Wang M; Chen J
Environ Mol Mutagen; 2014 Jun; 55(5):421-7. PubMed ID: 24535941
[TBL] [Abstract][Full Text] [Related]
2. Functional variants in cell death pathway genes and risk of pancreatic cancer.
Yang M; Sun T; Wang L; Yu D; Zhang X; Miao X; Liu J; Zhao D; Li H; Tan W; Lin D
Clin Cancer Res; 2008 May; 14(10):3230-6. PubMed ID: 18483392
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
4. Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma.
Zhu J; Qin C; Wang M; Yan F; Ju X; Meng X; Ding Q; Li P; Yang J; Cao Q; Zhang Z; Yin C
Mol Carcinog; 2010 Sep; 49(9):810-7. PubMed ID: 20572163
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions.
Hsu PI; Lu PJ; Wang EM; Ger LP; Lo GH; Tsay FW; Chen TA; Yang HB; Chen HC; Lin WS; Lai KH
Anticancer Res; 2008; 28(1A):97-103. PubMed ID: 18383830
[TBL] [Abstract][Full Text] [Related]
6. The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis.
de Martino M; Haitel A; Schatzl G; Klingler HC; Klatte T
J Urol; 2013 Aug; 190(2):717-22. PubMed ID: 23313206
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in cell death pathway genes are associated with altered sperm apoptosis and poor semen quality.
Ji G; Gu A; Hu F; Wang S; Liang J; Xia Y; Lu C; Song L; Fu G; Wang X
Hum Reprod; 2009 Oct; 24(10):2439-46. PubMed ID: 19542541
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms in promoter region of FAS and FASL gene and risk of cardia gastric adenocarcinoma.
Zhou RM; Wang N; Chen ZF; Duan YN; Sun DL; Li Y
J Gastroenterol Hepatol; 2010 Mar; 25(3):555-61. PubMed ID: 20074157
[TBL] [Abstract][Full Text] [Related]
9. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
[TBL] [Abstract][Full Text] [Related]
10. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population.
Wang LH; Ting SC; Chen CH; Tsai CC; Lung O; Liu TC; Lee CW; Wang YY; Tsai CL; Lin YC
J Oral Pathol Med; 2010 Feb; 39(2):155-61. PubMed ID: 20359312
[TBL] [Abstract][Full Text] [Related]
12. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of death pathway genes FAS and FASL and risk of nasopharyngeal carcinoma.
Cao Y; Miao XP; Huang MY; Deng L; Lin DX; Zeng YX; Shao JY
Mol Carcinog; 2010 Nov; 49(11):944-50. PubMed ID: 20842669
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in cell death pathway genes and HBV-related hepatocellular carcinoma among a Chinese Han population.
Liu F; Li F; Luo L; Yang H; Wei Y; Wang W; Yan L; Wen T; Yang J; Li B
Apoptosis; 2017 Aug; 22(8):1035-1047. PubMed ID: 28643196
[TBL] [Abstract][Full Text] [Related]
15. Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection.
Jung YJ; Kim YJ; Kim LH; Lee SO; Park BL; Shin HD; Lee HS
Intervirology; 2007; 50(5):369-76. PubMed ID: 17938571
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.
Daripally S; Nallapalle SR; Katta S; Prasad VV
Tumour Biol; 2015 Sep; 36(10):7817-30. PubMed ID: 25944167
[TBL] [Abstract][Full Text] [Related]
17. Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer.
Liamarkopoulos E; Gazouli M; Aravantinos G; Tzanakis N; Theodoropoulos G; Rizos S; Nikiteas N
Gastric Cancer; 2011 Oct; 14(4):317-21. PubMed ID: 21461653
[TBL] [Abstract][Full Text] [Related]
18. Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6N ins/del promoter polymorphism (rs3834129) in breast cancer.
Hashemi M; Eskandari-Nasab E; Fazaeli A; Rezaei H; Mashhadi MA; Arbabi F; Taheri M
Gene; 2012 Aug; 505(1):176-9. PubMed ID: 22659694
[TBL] [Abstract][Full Text] [Related]
19. CASP8 -652 6N del polymorphism and cancer risk: a meta-analysis of 30 case-control studies in 50,112 subjects.
Zhang F; Yang Y; Guo C; Wang Y
Mutagenesis; 2012 Sep; 27(5):559-66. PubMed ID: 22513478
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of IL-1A, IL-1B, IL-1RN, NFKB1, FAS, and FASL, and risk of silicosis in a Chinese occupational population.
Wu F; Xia Z; Qu Y; Tang Y; Cao D; Sun P; Christiani DC
Am J Ind Med; 2008 Nov; 51(11):843-51. PubMed ID: 18666137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
